Drug-eluting stent sales stimulate growth in the European interventional
13 November 2005
The European market for interventional cardiology generated over $1.4
billion in 2004, and will sustain a compound annual growth rate (CAGR)
exceeding 7% over the next 5 years, according to a new report by Millennium
Research Group (MRG).
Coronary artery disease (CAD) results from atherosclerosis, a condition that
narrows the arteries due to the deposition and build-up of arterial plaque
along the inner vessel walls. CAD is the most common form of heart disease
in Europe and one of the leading causes of death worldwide.
Over the past decade, the number of patients treated surgically through a
coronary artery bypass graft (CABG) procedure has declined in favour of the
less invasive percutaneous coronary intervention (PCI) method. Compared to
CABG, PCIs reduce ambulation time, lower the risk of death during the
procedure, and accelerate patient recovery time. As a result, the European
market for interventional cardiology devices is growing rapidly, driven by
the demand for drug-eluting stents (DES), the advent of new technologies,
and the rising volume of PCI procedures.
The 2002 introduction of Cordis’ CYPHER DES in Europe was a landmark
event for interventional cardiologists, and has since catapulted DES sales
along with Boston Scientific’s TAXUS, which was launched the following year.
DES have shown remarkable clinical advantages in reducing restenosis and
target vessel failure rates when compared to their bare-metal stent
predecessors. Although still limited by a premium price and reimbursement
lags in certain European regions, the penetration of DES units will be
rampant in upcoming years, particularly as more products are approved, new
indications are received, and more complex cases are able to be treated. The
European DES market will grow at a CAGR of over 15% through to 2009.
MRG’s European report is part of its Global Markets for Interventional
Cardiology series, which also includes analysis of the US, Japan, Latin
America, and Asia Pacific. The series covers over 50 key industry
competitors including Abbott Vascular (ABT), Biotronik, Boston Scientific
(BSX), Cordis (JNJ), Guidant (GDT), Medtronic (MDT), Sorin Biomedica, St.
Jude Medical (STJ), and Terumo.